who.int/tb/publications/global_report/2010/en] 2. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845–855.PubMed 3. Lin PL, Flynn JL: Understanding latent
tuberculosis: a moving target. J Immunol 2010, 185:15–22.PubMedCrossRef 4. Tufariello JM, Chan J, Flynn JL: Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Selleckchem SC75741 Dis 2003, 3:578–590.PubMedCrossRef 5. Kaufmann SHE: How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001, 1:20–30.PubMedCrossRef 6. Cooper AM, Khader SA: The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 2008, 226:191–204.PubMedCrossRef 7. Cole ST: Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS
Let 1999, 452:7–10.CrossRef 8. Cole selleck chemicals ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry III CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537–544.PubMedCrossRef
9. Bonanni D, Rindi L, Lari N, Garzelli C: Immunogenicity of mycobacterial PPE44 (Rv2770c) in Mycobacterium bovis BCG-infected mice. J Med Microbiol 2005, 54:443–448.PubMedCrossRef 10. Romano M, Rindi L, Korf H, Bonanni D, Adnet PY, Jurion F, Garzelli Florfenicol C, Huygen K: Immunogenity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine 2008, 26:6053–6063.PubMedCrossRef 11. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E: Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003, 283:141–153.PubMedCrossRef 12. Aiken AM, Hill PC, Fox A, McAdam KPWJ, Jackson-Sillah D, Lugos MD, Donkor SA, Adegbola RA, Brookes R: Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006, 6:66.PubMedCrossRef 13. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, Marocco R, Del Borgo C, Soscia F, Vullo V, Mastroianni CM: In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-γ T cell response. Plos ONE 2009, 4:e5187.PubMedCrossRef 14. Rindi L, Peroni I, Lari N, Bonanni D, Selleckchem PD-1/PD-L1 inhibitor Tortoli E, Garzelli C: Variation of the expression of Mycobacterium tuberculosis ppe44 gene among clinical isolates. FEMS Immunol Med Microbiol 2007, 51:381–387.